Division of NantWorks LLC
Latest From NantCell LLC
The latest oncology development news and highlights from our US FDA Performance Tracker.
While the proposed Bristol/Celgene merger nears an April vote, Celgene continues a recent spate of deal-making, paying $25m up front to Exscientia to discover small molecule candidates for cancer and autoimmune disease.
Cancer drug-developer Black Diamond emerges from stealth mode with Series A and closes Series B in the same month, while aging-focused Juvenescence closes its initial tranche and looks complete Series B by the end of the quarter.
A review of biopharma start-up deal-making and financing activity from July through September 2017, based on data from Strategic Transactions, showed that fundraising declined 18% from the previous quarter, however the number of acquisitions doubled to eight.
Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Drug Discovery Tools
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- NantWorks LLC
- Senior Management
- Patrick Soon-Shiong, PhD, CEO
- Contact Info
Phone: (310) 883-1300
9920 Jefferson Blvd.
Culver City, CA 90232
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.